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Abstract (196 words) 
 
Purpose of Review:  Providing EPA and DHA, in the form of fish oils, to benefit muscle is an emerging area of interest.  The aim of 
this work was to evaluate the current literature that has assessed muscle mass as an outcome during a fish oil intervention in any 
chronic disease.  
 
Recent Findings:  The vast majority of studies published in the last 3 years (12 out of 15) have been conducted in the oncological 
setting, in patients undergoing treatment for cancers of the gastrointestinal tract, breast, head and neck, lung, cervix and 
hematological cancers. Three studies were conducted in patients with COPD. Fish oil was provided as part of a nutrient mixtures in 
12 studies and as capsules in 3 studies.  
 
Summary:  Overall the evidence for an effect of fish oil supplementation on muscle mass in cancer patients undergoing treatment 
and in COPD remains unequivocal and reveals nothing new in the area of fish oil supplementation in the cancer setting which 
continues to provide mixed evidence on the efficacy of fish oil on muscle mass and function. This review highlights challenges in 













RCT  Randomised Controlled Trial 
PUFA PolyUnsaturated Fatty Acids 
ONS Oral Nutritional Supplement 
RA   Rheumatoid Arthritis 
GI  Gastrointestinal 
DXA   Dual x-ray Absorptiometry 
EPA eicosapentaenoic acid  
DHA docosahexaenoic acid 
COPD Chronic Obstructive Pulmonary Disesase  





Chronic disease generally occurs in older individuals and exacerbates the normal physiology of aging which includes muscle loss. 
Chronic disease is generally associated with some degree of inflammation and altered hormone regulation impacting muscle health 
(1). Low muscle mass is a feature common to many chronic diseases, and often exists even at the time of diagnosis, with additional 
losses anticipated during the trajectory of chronic disease evoked by the disease process itself or the medications prescribed for 
managing the condition (2, 3). Sedentary lifestyles and poor diets may also contribute to the development of chronic disease and 
have a negative impact on muscle health.  
 
Sarcopenia, or muscle mass below a specific threshold that is associated with disability, has received attention in recent years due to 
its association with poor outcomes in nearly all chronic diseases in which it has been evaluated. A more recent poor prognostic factor 
of low muscle attenuation (low muscle radiodensity) has been revealed by the opportunistic application of CT imaging and is 
associated with aberrant fat infiltration into muscle (4, 5). There have been several recent reviews on the association of body 
composition features with poor outcomes in aging (6), cancer (3), and chronic liver disease (7, 8). However, less is known about how 
to potentially modify these poor prognostic features with nutritional interventions.  
 
Dietary n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), 
have well described immune-modulating effects, and have been studied with respect to modification of the burden of chronic disease. 
EPA and DHA are nutrients found in fatty fish and their oils, and can be encapsulated or provided as a component of oral nutritional 
supplements. This review evaluates recent evidence (published in the past three years) to determine whether provision of EPA and 
DHA, in the form of fish oil, is associated with improved muscle mass and/or function in chronic diseases. 
 
Rationale for Study of EPA and DHA in Muscle Health 
 
A handful of elegant studies have yielded positive results with respect to an attenuation of aging associated muscle loss when EPA 
and DHA are provided to older individuals. During healthy aging, n-3 PUFA supplementation improves muscle protein synthesis, 
strength and function as well as muscle mass (9, 10) in the absence of changes in inflammation. Pathways that have been explored 
include insulin stimulated pathways and mitochondrial function, both of which are enhanced in older humans supplemented with n-3 
PUFA (11, 12). In conditions of insulin resistance, also common to many chronic diseases, n-3 PUFA improve insulin sensitivity even 
in the absence of gains in muscle mass (12-14). Nearly two decades of research in the cancer setting has additionally provided 




Status of n-3 fatty acids and Low muscle mass are generally independently evaluated in chronic diseases 
 
Poor status of n-3 PUFA has been reported in many chronic diseases where low mass muscle mass has been reported separately 
including Rheumatoid Arthritis (RA) (17), Chronic Obstructive Pulmonary Disease (COPD) (18-20), liver disease (Non Alcoholic Fatty 
Liver Disease and cirrhosis) (21, 22); cancer (23-25); diabetes (17, 26, 27), Chronic Kidney Disease (28), Heart Disease (29) and 
Alzheimer’s disease (30-32). The two features of poor n-3 PUFA status and low muscle mass may be related events rather than 
isolated events (23). Studies that have evaluated nutritional interventions with fish oils typically evaluate disease markers, and/or 
inflammation. These outcomes are rarely evaluated in tandem with body composition. Further, to our knowledge, no study has 
directly investigated mechanisms of action of EPA and DHA to evaluate a change in muscle protein synthesis and protein breakdown 
in a chronic disease condition.    
 
Update on n-3 PUFA interventions in Chronic Disease where Muscle is Assessed as an outcome 
 
A broad search of the literature over the past three years revealed 15 studies that have applied an n-3 PUFA intervention and 
measured muscle or lean body mass as an outcome. Twelve of these studies were conducted in the oncology setting; the additional 
three studies were conducted in COPD. Therefore, a major gap in the literature are studies that assess muscle mass during an n-3 
PUFA intervention in other chronic diseases associated with muscle loss, such as RA and liver disease.  
 
Cancer   
 
The majority of people diagnosed with cancer experience muscle loss during their disease trajectory. The importance of maintaining 
muscle mass in the oncology setting is well established (33, 34). Loss of muscle is accelerated in cancer due to tumor metabolism, 
delivery of toxic drugs and limited food intake. N-3 PUFA supplementation studies in patients undergoing active treatment published 
since the early 2000s documented benefits on tumor response, prevention of toxicities, inflammation and maintenance of muscle 
mass (15, 35, 36). Studies published in the past three years were conducted in patients gastrointestinal (4 studies), head and neck (3 




Four studies were conducted in patients with gastrointestinal cancer, including gastric, pancreatic and colorectal cancer, undergoing 
neoadjuvant chemotherapy or surgery. Sample sizes ranged from 20-34 per group. None of the studies evaluated outcome 
measures separately for men and women. The age of the participants varied from 30 y to 90 y to include a broad range of expected 
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muscle mass. All nutritional interventions for GI cancers used mixtures containing EPA and DHA, with three studies applying an 
ONS, and one study using capsules to provide fish oil alone or in combination with vitamin D. Two of three studies using an ONS 
provided additional calories and protein compared to the “control” intervention (37-39), one study (40) matched the control group with 
an equivalent amount of calories and protein. Compliance to the supplement was either not reported or reported to be a challenge 
impeding interpretation of the results. Results were varied with no effect, weight gain and increase in muscle mass being reported 
following the intervention. In the single study that used capsules containing vitamin D and fish oil, four groups were evaluated: 1) 
placebo, 2) fish oil, 3) vitamin D and 4) fish oil plus vitamin D. For each group, placebo capsules were provided. This study reported 
an increase in fat free mass in the fish oil groups (with and without vitamin D) (41).   
 
Head and Neck Cancer 
 
All of the studies conducted in the head and neck population used a nutrient mixture in the form of ONS. Two of the studies were 
comparable with respect to the supplement provided as well as duration of the intervention (42, 43). Neither of these studies showed 
an effect of supplementation on any of the assessed parameters. The third study provided ONS containing EPA and DHA during 6 
weeks of treatment (44). Using a similar dose as other studies (2 g EPA/d), this group showed a stabilization of body weight and lean 
body mass, whereas the control group lost both weight and lean body mass. The intervention group also experienced an 
improvement in fatigue and measures of inflammation. Results of these studies are reported as a change over time in the 
intervention group rather than between groups as intended. Poor compliance to ONS is expected in this group experiencing a high 




Two randomised controlled trials (RCTs) evaluated EPA and DHA in breast cancer patients; one during a chemotherapy regimen 
(45) and one in treatment naive patients awaiting surgery (46), therefore the intervention duration was different between the studies. 
Both studies provided EPA and DHA in the form of capsules. No changes in fat free mass neither during the intervention nor between 




The other cancer categories included malnourished cervical cancer patients (47), weight losing NSCLC patients (48), and patients 
with mixed types of hematological malignancies (49). In cervical cancer patients, no absolute difference between intervention groups 
was reported for lean body mass (47). Laviano et al. reported no difference in lean body mass between a group of NSCLC patients 
receiving a nutrient mixture containing EPA and DHA compared to a placebo. Chagas et al. reported greater mid arm muscle 
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circumference in hematological cancer patients prescribed fish oil capsules during 9 weeks of treatment. Reporting results as a 
function of compliance resulted in small sample sizes in each subgroup.   
 
 
Chronic Obstructive Pulmonary Disease (COPD) 
 
Three studies in the past 3 years evaluated an n-3 PUFA supplementation in COPD patients, albeit having very different study 
designs (50-52). Calder et al. provided two containers of an ONS containing 1200 mg DHA and 800 mg EPA per day. Plasma n-3/n-6 
ratios showed 79% of the intervention group achieved compliance. Improvements in symptoms (fatigue, dyspnea, walking distance) 
were observed, however, there were no changes in inflammation markers, activity scores, appetite or muscle mass after a 12 week 
intervention (50).  
 
A second study in COPD patients in an open label study design provided a fish oil containing ONS during hospitalization for an acute 
phase of disease activity. On average, patients were hospitalized for one week and remained on the supplement until discharge. 
Longer hospital stay (receiving more supplements over time) was positively correlated with lean body mass (51).  
 
A third study was conducted in COPD patients with low muscle mass who were undergoing rehabilitation on an outpatient basis. The 
nutritional intervention was comprised of a mixture of EPA and DHA, with leucine and vitamin D provided for 4 months concurrent 
with an intense exercise program. The control group received a placebo drink, therefore groups were not matched for calories or 
protein. Importantly, however, this study assessed the plasma levels of EPA and DHA at baseline and also compared these values to 
healthy controls. Both groups receiving n-3 PUFA experienced improved skeletal muscle mass, quadriceps muscle strength and 
cycle endurance time, inspiratory muscle strength only improved in the supplement group. Therefore there was an effect on function 
without a change in muscle mass (52).   
 
Summary of Recent Literature 
 
The studies applying fish oil interventions to evaluate effects on muscle health are currently almost exclusively been conducted in the 
oncology setting. Collectively, the literature over the past 3 years conducted in cancer and COPD does not strengthen the evidence 
base to support fish oil intervention to maintain muscle mass and there were no two studies that were similar in intervention, disease 
state, and outcomes. In general, studies suffer from limited, and often unjustified sample sizes where subgroup effects (such as age, 
sex or tumor site) are not able to be explored. A limitation in the ability to interpret studies also lies in the reporting of a change within 
the supplemented group over time, whereas in a RCT design, the difference between the two groups should be evaluated. Studies 
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reporting change over time in the intervention group when a difference between groups was not observed causes a bias to 
overestimate effects. Study design considerations for future studies are highlighted in Figure 1. 
 
The prescribed dose of n-3 PUFA is generally reported, but not the actual dose taken. Only 4 out of 15 studies reported a biological 
measure of compliance. The prevailing literature suggests that an effective dose of fish oil is approximately 2 g per day (15, 16, 53-
55), but whether that is total n-3, EPA and/or DHA remains to be determined. Dose justification is not referenced in the majority of 
reviewed studies and some used a lower dose (e.g. 1 g EPA per day). Poor compliance to fish oil containing supplements has been 
known for >15 years, therefore not having a measure of compliance is problematic. When there is no biological measure of 
compliance, one cannot relate the outcome measure to a specific amount of EPA or DHA achieved during the supplemental period.  
This information is required to enable an estimation of the required amount of EPA and DHA required to see a benefit should one 
exist. This remains a major gap in the area of nutritional supplementation studies. Importantly, EPA and DHA are dietary essential 
nutrients and patients with cancer (56) and COPD (52) have levels of EPA and DHA that are lower than comparable controls in the 
healthy population, which could be a result of the disease process, altered metabolism, poor diets, or a difference in essential fatty 
acid requirements. With the absence of plasma measures of n-3 fatty acids, it is challenging to know whether EPA and DHA are 
“supplemented” or restored nor do we know the level required to see a biological impact on the outcome of interest.  
 
Studies showed no attention to or mention of age, sex or co-morbidities. Having specific diagnoses that affect muscle is often an 
exclusion criteria for entry into RCT that evaluate muscle mass. However, apart from diagnosed diseases per se, cancer patients are 
known to have one or more comorbidities at presentation (57). This contributes to poor muscle condition (58) in addition to the 
medications prescribed to manage those conditions. None of the studies evaluated men and women separately. It is known that 
there is considerable sexual dimorphism in muscle responses and responses to interventions (59-61). In order to better understand 
who is most likely to benefit from interventions, the analysis needs to account for this. Food intake and EPA and DHA intake from 
other sources is rarely assessed, even though the baseline diet is a key consideration in whether or not a person may respond to 
supplemental EPA and DHA. Further, adequate energy and muscle building nutrients are required to reach an anabolic response.  
 
Perhaps even more important than muscle mass, is muscle function. Two studies that included an evaluation of muscle function 
showed a benefit. No study evaluated mechanisms although some associations of muscle mass with markers of inflammation in the 
blood were attempted recognizing inflammation to be driving muscle loss in chronic disease. The majority of studies applied bio-
impedance analysis (BIA) to measure their primary outcome of muscle mass or lean body mass, however, BIA assesses fat free 






The set of literature published in the past 3 years does not strengthen the base of mixed evidence that has built over the past 
decades investigating muscle loss that occurs in chronic disease. The literature continues to provide mixed evidence on the efficacy 
of EPA and DHA for muscle mass and only reports on studies conducted in COPD and cancer. ESPEN guidelines for oncology 
patients recommend the use of fish oil supplements during cancer treatment and in patients expected to experience muscle loss 
however, this recommendation is based on weak evidence. The most recent systematic review effects of fish oils in the cancer 
setting concluded that provision of fish oils concurrent with chemotherapy is beneficial to body composition, an effect only seen in 
well-designed studies (15, 53).  As has been previously reported, the safety and lack of harm from of n-3 PUFA supplementation was 
evident. However, to obtain more evidence base, RCTs in large, homogenous groups are needed.  This can be achieved by forging 
collaborations between research groups and clinicians and to conduct multi-centre trials to enhance the evidence required to move 




● Few studies outside of oncology have applied fish oil supplementation in tandem with measures of muscle mass 
● Due to study design limitations, the evidence base on the benefit of fish oil on muscle mass is not enhanced by recently 
published research 
● Clinical trials applying fish oil supplementation currently do not account for expected differences in age, sex, dietary intakes 
and co-morbidities as contributors to muscle mass 
● Reporting on and measuring compliance remains an obstacle to building an evidence base in the area of fish oil 





FIGURE 1:  A checklist of considerations for future studies designed to assess a nutritional intervention on muscle mass in chronic 
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Figure 1. Study Design Checklist 
 
Study Design Checklist 
 
• Use an RCT design (preferably double blinded) and 
follow the PRISMA guidelines  
 
• Use intention-to-treat analysis and report 
comparisons between groups rather than within 
groups 
 
• Use an adequate sample size to ensure statistical 
power to compare on primary (and secondary) 
outcome(s) 
 
• Report patients % weight loss, tumour type, tumor 
stage and inflammatory status at baseline 
 
• Monitor and report patients dietary energy and protein 
intake at baseline and follow up during the study 
 
• Assess plasma fatty acids at baseline and at the end 
of the intervention as a measure of compliance and to 
determine a dose response should one exist 
 
• Report supplement composition in terms of content of 
EPA and DHA prescribed 






Patient Population and  
Sample Size 















Gastric cancer patients 







DHA: 900 ONS 
Standard 
ONS 30 days Weight 






67.8 + 10.7y 
11M:20F 
EPA: 2200 






Aoyama et al., 2019  






Gastric cancer (Roux en Y) 
surgery  
(n=60) 
30-80 y  
43M:17F 
EPA : 2200 
DHA: 900 ONS Regular Diet 
pre-operatively 
for 6 days plus 21 
days post surgery 
after oral intake 
resumed Lean body mass 
Haidari et al., 2019 
 RCT 
Colorectal cancer, n=80 (3 
intervention groups with 
fish oil ± vitamin D and a 
control group; 
n=20/group) 
56.7 ± 12.5 y 
46M:35F 
EPA: 1100 
DHA: 500 Capsules Placebo 
2 Capsules/d for 
8 weeks (with 
and without 






Head and Neck Cancer 
Hanai et al., 2018 RCT 





EPA : 2200 
DHA: 900 ONS 
Standard 
ONS 
14 days prior to 





al., 2018 RCT 




55.2 ± 13.5 y   
60M:12F  
EPA: 2200 
DHA: 900 ONS 
Standard 
ONS 
7 days prior to 
surgery and 14 
days post 
operatively Weight 
Solis-Martinez et al., 
2018 RCT 
Head and Neck cancer  
(n=64) 
59 ± 14y 
35M:29F 
EPA: 2000 
DHA: ? ONS 
Isocaloric 





De la Rosa et al., 
2019 RCT 
Breast Cancer Patients 
undergoing neoadjuvant 





DHA: 800 Capsules 
Placebo 
capsules  6 months 
Body 
composition 
Paixao et al.,  
2017 RCT 






DHA: 780 Capsules 
Mineral oil 
capsules 





Aredes et al., 2019 RCT 
Cervical cancer patients 
Treatment naive and 
those who had undergone 






DHA: 500 Capsules 
Placebo 






Laviano et al, 2019 RCT [Pilot] 
Weight losing NSCLC 
patients undergoing first 
line chemotherapy (n=54) 
64.4±7.7  y 
38M: 17F 
EPA: 1600 
DHA: 2400 ONS 
Standard 
Comparator 12 weeks 
Safety and 
efficacy 






43.8 + 23.3 y 
12M:10F   
EPA: 367 
DHA: 243 Capsules 
Placebo 
capsules  9 weeks 
Nutritional 
status 
Chronic Obstructive Pulmonary Disease 





COPD,  pre-cachectic and 
cachectic 
(n=45) 
69.2 ± 6.3 y 
 45M:55F 
EPA: 1600 
DHA: 2400 ONS 
Standard 
Comparator 12 weeks Lean body mass 








77.4 ±9.7 y 
41M:  4F 
EPA: 1100 
DHA: 450 ONS   
hospital stay 
(mean = 12.6 +/- 
4.9 d, EPA group, 
12.1+/-3.9 d, 
control group) Lean body mass 
van de Bool et al., 
2017 RCT 











liquid drink  4 months 
Body weight, 




aAge reported for the Intervention group 
bNumber of males and females in total reported 
 
Table 2:  Outcomes Assessed in Recent Literature 







Food Intake? Measure of 
Inflammation? 
Feijo, Nutrition Journal 
2019 
X X X  
(BIA) 
    
Akita, Clin Nutr ESPEN 
2019 
X X X  
(BIA and psoas by CT) 
X x 
Aoyama, J Cancer 
2019 & Ida, BJS 2017 
X X X  
(BIA) 
X x 
Haidari, J Diet Suppl 
2019 
X X X  
(BIA) 
X   





X X X  
(BIA) 
X   
Solis-Martinez, Nutr 
Ca 2018 
X X X  
(BIA) 
  x 
De la Rosa et al, 
Nutricion Hospitalaria 
2019 
X X X  
(BIA) 
X   
Paixao, Nutr J 2017 X X X  
(BIA) 
    
Aredes, Nutrition 2019 X X X  
(unvalidated CT 
measure of psoas) 
  x 
Laviano, Nutr Cancer 
2019 
  X   
(Undescribed 
DXA and CT) 
X x 
Chagas, J Hum Nutr   X   x   
Diet 2017 (anthropometrics) 
Calder, J Cachexia, 
Sarcopenia and 
Muscle 2018 
      
(DXA) 
    
Ogasawara, Clin Nutr 
ESPEN 2018 
X X X  
(BIA) 
x x 
van de Bool, J Cach 
Sarc Muscle 2017 
       
(DXA) 
x x 
X no yes 
 
 
